Genmab and partner Johnson & Johnson will not support the extension of the user application of cancer treatment Darzalex, shows a document draft from the UK National Institute for Health and Clinical Excellence (NICE), which advises England and Wales on medications, reports sector media Pharmatimes.
In the document, NICE grounds its conclusion citing concerns about the long-term effect of using Darzalex in combination with Velcade, Thalidomid and Dexamethason as first-line treatments for bone marrow cancer with patients well suited for stem cell transplantation.
Today, patients are typically treated with the same cocktail of drugs excluding Darzalex. NICE also bases its decision on concerns of cost relative to effect, Pharmatimes writes.
European heath authorities issued approval for Darzalex in the aforementioned combination back in 2020 as an initial treatment of patients for whom stem cell transplantation is deemed appropriate.
Genmab: Janssen dispute cost DKK 146m in H1
Genmab's successful CEO dismisses retirement plans
Analyst: Genmab may upgrade financial guidance based on Darzalex sales figures
More from MedWatch
EU Commission proposes staggered transition to new medtech requirements after industry warnings
After criticism for a lack of clarity on the regulation for medtech devices from doctors and industry players, the EU Commission has proposed an extension of the transition period.
Danish agency joins competition authority chorus in criticizing Oticon Medical sale
The Danish competition authorities are the latest to express concern over the potential sale of Demant’s Oticon Medical division to Cochlear.
New majority owner makes several board appointments at hearing firm
Eargo’s new majority shareholder, Patient Square Capital, is now represented by several board members.
Full house for Ambu – all products live up to new EU requirements
Medtech company Ambu can boast that all of its products live up to the MDR directive, which has introduced stricter requirements for medical equipment.
FDA approves new sensor for insulin pens
A new type of sensor which is able to collect and transmit key treatment information has been approved by the FDA.
Head of Engineering 
Project Director of CMC & Device, Zealand Pharma A/S / 1801 
Consultants for FIERS - will you create unique healthcare collaborations? - FIERS - Copenhagen / Denmark 
Nordic Medical Manager, Central Nervous System 
Quality Compliance Specialist - Herbal Medicines and Medical Devices 
Supply Chain Manager 
Senior or Principal Scientist – Preclinical Biology 
Laboratory assistants for an exciting QC department 
Chief consultant for Dansk Erhvervs Health and life science 
Senior Laboratory Technician 
Systems Verification Manager for Embedded Medical Solutions